CSN Login
Members Online: 3

Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels

hopeful and opt...
Posts: 1542
Joined: Apr 2009

Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: A single institution analysis - Abstract


PURPOSE: Purpose of this study is to analyze outcomes and pre-treatment prognostic factors in high-risk prostate cancer patients with initial PSA ≥20 ng/mL, treated with high-dose external beam radiotherapy (EBRT) and androgen deprivation therapy (ADT) in a single institution.

METHODS: Between March 2003 and December 2011, 155 consecutive high-risk prostate cancer patients (a) presenting with pre-treatment PSA level ≥20 ng/mL, (b) treated with definitive EBRT, and (c) with a minimum follow-up of 24 months were included in this retrospective analysis. Phoenix definition was used to define biochemical control. Primary endpoints were as follows: biochemical disease-free survival (bDFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS) and overall survival (OS). Multivariate analysis was performed to determine the independent prognostic impact of pre-treatment clinical factors [T stage, PSA, and Gleason score (GS)].

RESULTS: At a median follow-up time of 62 months, actuarial bDFS, DMFS, CSS, and OS at 5 years were 64.8, 85.2, 95.8, and 94.4 %, respectively. On multivariate analysis, only GS was significantly associated with three clinical endpoints (bDFS: HR 1.6; p = 0.022, CSS: HR 4.27, p = 0.044, OS: HR 2.6; p = 0.038). Pre-treatment zenith PSA was associated only with bDFS (HR 1.87; p = 0.027).

CONCLUSIONS: Patients with "high" PSA levels (≥20 ng/mL) showed favorable clinical outcomes, supporting the role of local radiotherapy as primary therapy in combination with long-term ADT in patients with high PSA levels at diagnosis. A GS of 8-10 is the strongest predictor of outcome.

Written by: 
Guarneri A, Botticella A, Filippi AR, Ruggieri A, Piva C, Munoz F, Ragona R, Gontero P, Ricardi U.   Are you the author? 
Radiation Oncology, San Giovanni Battista Hospital, University of Torino, 10126, Turin, Italy.

Reference: J Cancer Res Clin Oncol. 2013 Apr 4. Epub ahead of print. 
doi: 10.1007/s00432-013-1426-0

PubMed Abstract
PMID: 23552872

UroToday.com Prostate Cancer Section

Posts: 42
Joined: May 2013

Very interesting Hopeful - I'm looking forward to reading the article.

Please keep them coming!


Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2015 © Cancer Survivors Network